Arizona and 36 other states are part of a $90 million settlement with drug manufacturer GlaxoSmithKline for its deceptive promotion of a diabetes drug.

Arizona's share of the settlement is $3,043,664, according to Arizona Attorney General Tom Horne.

The company misrepresented the cardiovascular risks and claimed incorrectly that it could lower cholesterol in advertisements for the diabetes drug Avandia, Horne said in a news release.

A portion of the money will be put into the state's Consumer Fraud Revolving Fund and used to cover attorneys fees for future consumer investigations, Horne said.

The remainder, about $2.4 million, will be used in new state programs to reduce childhood obesity in Arizona. That's because childhood obesity can lead to Type II diabetes later in life.

Also as part of the settlement, GlaxoSmithKline is required to change how it advertises its diabetes drugs, including not making claims that aren't supported by evidence or clinical trials.